Estimates Revisions Vanda Pharmaceuticals Inc.
Stocks
VNDA
US9216591084
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
00:00:00 03/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 4.630 USD | -3.74% |
|
-8.32% | -47.51% |
| 08-24 | Vanda Pharmaceuticals' Skin Disease Drug Gets EU Orphan Drug Designation | MT |
| 08-10 | B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- VNDA Stock
- Consensus Vanda Pharmaceuticals Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
